pimavanserin: A 5-HT(2A) inverse agonist; ACP-103 is the dihydroxybutanedioate (2:1) salt. It is used to treat hallucinations and delusions associated with PARKINSON DISEASE; structure in first source. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
pimavanserin : A member of the class of ureas in which three of the four hydrogens are replaced by 4-fluorobenzyl, 1-methylpiperidin-4-yl, and 4-(isopropyloxy)benzyl groups. An atypical antipsychotic that is used (in the form of its tartrate salt) for treatment of hallucinations and delusions associated with Parkinson's disease. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 10071196 |
| CHEMBL ID | 2111101 |
| CHEBI ID | 133017 |
| SCHEMBL ID | 675165 |
| MeSH ID | M0498685 |
| Synonym |
|---|
| AC-5273 , |
| acp-103 |
| CHEBI:133017 , |
| pimavanserin |
| 706779-91-1 |
| n-(4-fluorophenylmethyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy)phenylmethyl) carbamide |
| n-[(4-fluorophenyl)methyl]-n-(1-methylpiperidin-4-yl)-n'-{[4-(2-methylpropoxy)phenyl]methyl}urea |
| FT-0653701 |
| n-[(4-fluorophenyl)methyl]-n-(1-methyl-4-piperidinyl)-n'-[[4-(2-methylpropoxy)phenyl]methyl]urea; |
| A836958 |
| n-(4-fluorophenylmethyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy)phenylmethyl)carbamide |
| unii-jz963p0dik |
| pimavanserin [inn] |
| jz963p0dik , |
| AKOS015902593 |
| 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1-methylpiperidin-4-yl)urea |
| pimavanserin [mi] |
| pimavanserin [who-dd] |
| DB05316 |
| CS-3378 |
| HY-14557 |
| SCHEMBL675165 |
| pimanavserin |
| ME-0240 |
| J-503297 |
| bdbm139370 |
| RKEWSXXUOLRFBX-UHFFFAOYSA-N |
| CHEMBL2111101 |
| nuplazid (proposed trade name) |
| gtpl8423 |
| 1-[(4-fluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)-3-[[4-(2-methylpropoxy)phenyl]methyl]urea |
| n-[(4-fluorophenyl)methyl]-n-(1-methyl-4-piperidinyl)-n'-[[4-(2-methylpropoxy)phenyl]methyl]-urea; n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n'-[[4-(2-methylpropyloxy)phenyl]methyl]carbamide; pimavanserin |
| NCGC00390656-01 |
| methyltrimethylacetate |
| pimavanserin(acp-103) |
| 706779-91-1 (free base) |
| pimavanserin free base |
| DTXSID90990906 |
| BCP11618 |
| Q7194603 |
| EX-A4895 |
| SB16963 |
| HMS3742A03 |
| NCGC00390656-02 |
| EN300-19659487 |
| 1-[(4-fluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)-3-{[4-(2-methylpropoxy)phenyl]methyl}urea |
| pimavanserinum |
| n05ax17 |
| pimavanserina |
| n-((4-fluorophenyl)methyl)-n-(1-methylpiperidin-4-yl)-n'-((4-(2-methylpropoxy)phenyl)methyl)urea |
| pimavanserine |
Pimavanserin is a 5HT2A inverse agonist that is the only Food and Drug Administration-approved treatment for Parkinson disease (PD) psychosis.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Pimavanserin is a selective 5-HT" | ( Improving the treatment of Parkinson's disease: Structure-based development of novel 5-HT Dai, Y; Du, G; Liu, B; Liu, W; Ma, M; Tian, J; Wang, W; Xu, H; Yang, H; Yang, Y; Ye, L; Zhang, J; Zhang, R; Zheng, L; Zhu, X; Zou, F, 2022) | 2.16 |
| "Pimavanserin is a novel agent approved for the treatment of Parkinson's disease and exerts neuroprotective properties." | ( The protective effects of Pimavanserin against cerebral ischemia-induced brain injury. Li, X; Tian, X, 2021) | 1.64 |
| "Pimavanserin is a selective serotonin 5-HT 2A receptor inverse agonist/antagonist being investigated in patients with negative symptoms of schizophrenia. " | ( Pimavanserin Exposure-Response Analyses in Patients With Schizophrenia: Results From the Phase 2 ADVANCE Study. Bugarski-Kirola, D; Darwish, M; DeKarske, D; Jaworowicz, D; Owen, J; Passarell, J; Stankovic, S, ) | 3.02 |
| "Pimavanserin is a serotonin 5HT-2A receptor inverse agonist that has recently been shown to reduce psychosis related to dementia." | ( [Pimavanserin and trazodone combination in behavioral disorders in severe dementia with Lewy bodies]. Blanc, F; Javelot, H; Merignac, J; Moog, C; Muller, C; Schorr, B, 2023) | 2.54 |
| "Pimavanserin is a 5-hydroxytryptamine-2A antagonist and inverse receptor agonist. " | ( A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Adjunctive Pimavanserin in Patients With Major Depressive Disorder and an Inadequate Response to Therapy (CLARITY). Dirks, B; Fava, M; Freeman, MP; Liu, K; Papakostas, GI; Shelton, RC; Stankovic, S; Thase, ME; Trivedi, MH, 2019) | 2.19 |
| "Pimavanserin is a receptor antagonist (5-HT2A, 5-HT2C) that has been given market authorization for psychosis occurring in Parkinson's disease." | ( New antipsychotic drugs for the treatment of agitation and psychosis in Alzheimer's disease: focus on brexpiprazole and pimavanserin. Cannavò, D; Caraci, F; Caruso, G; Drago, F; Leggio, GM; Salomone, S; Santagati, M, 2020) | 1.49 |
| "Pimavanserin is a novel 5-HT" | ( Pimavanserin: A Novel Antipsychotic for Parkinson's Disease Psychosis. Bozymski, KM; Crouse, EL; Gatesman, TL; Lowe, DK; Pasternak, KM, 2017) | 3.34 |
| "Pimavanserin is an effective treatment for PDP, and, like clozapine, it has very few negative effects on motor skills." | ( [Pimavanserin: a new treatment for the Parkinson's disease psychosis]. Duits, JH; Martens, HJM; Ongering, MS; Schulte, PFJ, ) | 1.76 |
| "Pimavanserin is a selective 5-HT" | ( Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study. Ballard, C; Banister, C; Coate, B; Cummings, J; Demos, G; Khan, Z; Owen, R; Stankovic, S; Youakim, JM, 2018) | 2.17 |
| "Pimavanserin (Pim) is a 5HT2A inverse agonist that is the only Food and Drug Administration-approved treatment for Parkinson disease (PD) psychosis. " | ( Pimavanserin for Psychotic Symptoms in People With Parkinsonism: A Second Chart Review. Friedman, JH, ) | 3.02 |
| "Pimavanserin is a 5-HT2A receptor inverse agonist/antagonist and is approved in the United States for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis." | ( Pimavanserin in Alzheimer's Disease Psychosis: Efficacy in Patients with More Pronounced Psychotic Symptoms. Ballard, C; Coate, B; Stankovic, S; Youakim, JM, 2019) | 3.4 |
| "Pimavanserin is a first-in-class selective serotonin 5-HT2A receptor inverse agonist approved for the treatment of Parkinson disease psychosis. " | ( Can pimavanserin help patients with Parkinson disease psychosis? Canal, C; de la Cruz, J, 2019) | 2.51 |
| "Pimavanserin is a newly approved treatment for Parkinson's disease psychosis, but real-world experience with pimavanserin has been limited by small sample sizes and limited assessment of longitudinal outcomes." | ( Pimavanserin for Psychosis in Parkinson's Disease-Related Disorders: A Retrospective Chart Review. Claassen, DO; Darby, RR; Farooque, A; Sellers, J, 2019) | 2.68 |
| "Pimavanserin is a selective serotonin 2A receptor (5-HT2AR) inverse agonist that has shown promise for treatment of psychotic symptoms in patients with Parkinson's disease. " | ( (11)C-labeling and preliminary evaluation of pimavanserin as a 5-HT2A receptor PET-radioligand. Andersen, VL; Dyssegaard, A; Hansen, HD; Herth, MM; Knudsen, GM; Kristensen, JL, 2015) | 2.12 |
| "Pimavanserin (ACP-103) is a selective inverse agonist of the 5-hydroxytryptamine 2A (5-HT2A) receptor intended to treat patients with Parkinson's disease psychosis (PDP). " | ( Pimavanserin. Anderson, KC; Cox, A; Hunter, NS, 2015) | 3.3 |
| "Pimavanserin is an inverse agonist at the 5HT2A receptor, with a lower binding affinity at the serotonin-2C receptor and sigma 1 receptor, but no significant binding to dopamine or other receptors." | ( Pimavanserin: An Inverse Agonist Antipsychotic Drug. Howland, RH, 2016) | 2.6 |
| "Pimavanserin (Nuplazid™) is a selective and potent serotonin 2A (5-HT2A) receptor inverse agonist and antagonist developed by ACADIA Pharmaceuticals that has been approved in the US as a treatment for patients with hallucinations and delusions associated with Parkinson's disease psychosis. " | ( Pimavanserin: First Global Approval. Markham, A, 2016) | 3.32 |
| "Pimavanserin is an antipsychotic with a unique mechanism of action (5-HT2A receptor inverse agonist) and no measurable dopaminergic activity; it has been demonstrated to be efficacious, well tolerated and safe for the treatment of PDP. " | ( Pimavanserin for the treatment of Parkinson's disease psychosis. Chendo, I; Ferreira, JJ, 2016) | 3.32 |
| "Pimavanserin is a new 5-HT2A receptor acting drug that has been given market authorization for psychosis in Parkinson׳s disease." | ( Inverse agonists - What do they mean for psychiatry? Blier, P; Drago, F; Nutt, D; Stahl, S; Wilson, S; Zohar, J, 2017) | 1.18 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Pimavanserin has a unique mechanism of action." | ( A New Hope in Alzheimer's Disease Psychosis: Pimavanserin. Akın, M; Kurhan, F, 2023) | 1.89 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Pimavanserin displays nanomolar potency as a 5-HT2A receptor inverse agonist, selectivity for 5-HT2A over 5-HT2C receptors, and no meaningful activity at any other G-protein coupled receptor." | ( On the discovery and development of pimavanserin: a novel drug candidate for Parkinson's psychosis. Burstein, ES; Hacksell, U; McFarland, K; Mills, RG; Williams, H, 2014) | 1.4 |
Pimavanserin is a selective serotonin 5-HT(2A) receptor inverse agonist. Treatment prevented 2,5-dimethoxy-4-iodoamphetamine hydrochloride-induced head twitches. It reversed the augmented locomotor response to amphetamine.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Pimavanserin-treated patients with ≥50% response in psychotic symptoms (n = 44) showed a greater improvement in agitation and aggression symptoms on the NPI-NH domain C (week six, least squares mean [LSM] difference = -3.64, t = -4.69, P < .0001) and the CMAI-SF (week six, LSM difference = -3.71, t = -2.01, P = .0483) than nonresponders (n = 32). " | ( Evaluation of the efficacy of pimavanserin in the treatment of agitation and aggression in patients with Alzheimer's disease psychosis: A post hoc analysis. Abler, V; Ballard, CG; Coate, B; Foff, E; Stankovic, S, 2020) | 2.29 |
| "Treatment with pimavanserin showed an acceptable tolerability profile." | ( Pimavanserin in Alzheimer's Disease Psychosis: Efficacy in Patients with More Pronounced Psychotic Symptoms. Ballard, C; Coate, B; Stankovic, S; Youakim, JM, 2019) | 2.3 |
| "Treatment with pimavanserin, a selective serotonin 5-HT(2A) receptor inverse agonist, prevented 2,5-dimethoxy-4-iodoamphetamine hydrochloride-induced head twitches, reversed the augmented locomotor response to amphetamine, and normalized prepulse inhibition in mice with amyloid pathology." | ( Pimavanserin, a 5-HT2A receptor inverse agonist, reverses psychosis-like behaviors in a rodent model of Alzheimer's disease. Bonhaus, DW; McFarland, K; Price, DL, 2012) | 2.16 |
Common adverse events were falls, urinary tract infections, and agitation. Safety, including collection of adverse events and the Mini-Mental State Examination (MMSE) and Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale Part III (MDS-UPDRS III) was assessed.
| Excerpt | Reference | Relevance |
|---|---|---|
| " Pharmacokinetic sampling was measured up to 216 hours after single oral/nasogastric doses of ACP-103 and after the last dose of once-daily oral administration of ACP-103 for 14 days." | ( Pharmacokinetics, tolerability, and safety of ACP-103 following single or multiple oral dose administration in healthy volunteers. Davis, RE; Mant, TG; Robbins-Weilert, D; van Kammen, DP; Vanover, KE; Weiner, DM; Wilbraham, DG, 2007) | 0.34 |
| " This methodology was effectively used to estimate Pimavanserin in vivo human (K2EDTA) plasma concentration for a clinical pharmacokinetic study." | ( A Fully Validated UHPLC-MS/MS Method for the Estimation of Pimavanserin in Human (K2EDTA) Plasma and its Application to a Clinical Pharmacokinetic Study. Aalapati, KK; Patnaik, RS; Singh, A, 2022) | 1.22 |
| Role | Description |
|---|---|
| antipsychotic agent | Antipsychotic drugs are agents that control agitated psychotic behaviour, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. |
| 5-hydroxytryptamine 2A receptor inverse agonist | An inverse agonist that binds to the same receptor as a 5-hydroxytryptamine 2A receptor agonist, but which induces a pharmacological response opposite to that agonist. |
| serotonergic antagonist | Drugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or serotonergic agonists. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| ureas | |
| piperidines | |
| monofluorobenzenes | Any member of the class of fluorobenzenes containing a mono- or poly-substituted benzene ring carrying a single fluorine substitutent. |
| aromatic ether | Any ether in which the oxygen is attached to at least one aryl substituent. |
| tertiary amino compound | A compound formally derived from ammonia by replacing three hydrogen atoms by organyl groups. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| cytochrome P450 family 3 subfamily A polypeptide 4 | Homo sapiens (human) | Potency | 21.3174 | 0.0123 | 7.9835 | 43.2770 | AID1645841 |
| G | Vesicular stomatitis virus | Potency | 37.9083 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| cytochrome P450 2D6 | Homo sapiens (human) | Potency | 5.3547 | 0.0010 | 8.3798 | 61.1304 | AID1645840 |
| Interferon beta | Homo sapiens (human) | Potency | 37.9083 | 0.0033 | 9.1582 | 39.8107 | AID1645842 |
| HLA class I histocompatibility antigen, B alpha chain | Homo sapiens (human) | Potency | 37.9083 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| Spike glycoprotein | Severe acute respiratory syndrome-related coronavirus | Potency | 39.8107 | 0.0096 | 10.5250 | 35.4813 | AID1479145 |
| Inositol hexakisphosphate kinase 1 | Homo sapiens (human) | Potency | 37.9083 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| cytochrome P450 2C9, partial | Homo sapiens (human) | Potency | 37.9083 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Cytochrome P450 1A2 | Homo sapiens (human) | IC50 (µMol) | 52.0000 | 0.0001 | 1.7740 | 10.0000 | AID1879795 |
| Cytochrome P450 3A4 | Homo sapiens (human) | IC50 (µMol) | 100.0000 | 0.0001 | 1.7536 | 10.0000 | AID1879798 |
| Cytochrome P450 2D6 | Homo sapiens (human) | IC50 (µMol) | 100.0000 | 0.0000 | 2.0151 | 10.0000 | AID1879760 |
| Cytochrome P450 2C9 | Homo sapiens (human) | IC50 (µMol) | 100.0000 | 0.0000 | 2.8005 | 10.0000 | AID1879796 |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | IC50 (µMol) | 0.0335 | 0.0001 | 0.8801 | 8.8500 | AID1380714; AID1654710; AID1800764; AID1879757; AID1879782 |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | Ki | 0.0009 | 0.0000 | 0.3855 | 10.0000 | AID1800763; AID1855112 |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | IC50 (µMol) | 0.0464 | 0.0001 | 1.0302 | 9.0000 | AID1800764 |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | Ki | 0.0012 | 0.0001 | 0.9549 | 10.0000 | AID1800763; AID1855113 |
| Cytochrome P450 2C19 | Homo sapiens (human) | IC50 (µMol) | 49.8000 | 0.0000 | 2.3983 | 10.0000 | AID1879797 |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | IC50 (µMol) | 0.0464 | 0.0001 | 1.1873 | 8.9125 | AID1800764 |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | IC50 (µMol) | 0.4100 | 0.0009 | 1.9014 | 10.0000 | AID1879765 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | Kb | 0.0006 | 0.0006 | 0.1689 | 1.1000 | AID1380714 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1347160 | Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347159 | Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1879817 | Drug distribution in Sprague-Dawley rat brain at 6 micromol/kg administered via gavage measured after 2 hrs by LC-MS/MS analysis | 2022 | European journal of medicinal chemistry, Apr-15, Volume: 234 | Improving the treatment of Parkinson's disease: Structure-based development of novel 5-HT |
| AID1879795 | Inhibition of CYP1A2 (unknown origin) | 2022 | European journal of medicinal chemistry, Apr-15, Volume: 234 | Improving the treatment of Parkinson's disease: Structure-based development of novel 5-HT |
| AID1879775 | Drug metabolism in rat assessed as AUC(0 to 24 hrs) for AC- 423 metabolite at 100 mg/kg by UHPLC/FT-ICR-MS analysis | 2022 | European journal of medicinal chemistry, Apr-15, Volume: 234 | Improving the treatment of Parkinson's disease: Structure-based development of novel 5-HT |
| AID1823828 | Antagonist activity at human 5-HT2A receptor expressed in human recombinant CHO-K1 cells co-expressing G protein alpha16 incubated for 1 hr by cellular aequorin-based functional assay | |||
| AID1823849 | Antipsychotic activity in ip dosed Wistar rat assessed as induction of MK801-induced hyperlocomotor activity by measuring minimum effective dose measured for 15 mins | |||
| AID1879768 | AUC(0 to 24 hrs) in monkey at 100 mg/kg by UHPLC/FT-ICR-MS analysis | 2022 | European journal of medicinal chemistry, Apr-15, Volume: 234 | Improving the treatment of Parkinson's disease: Structure-based development of novel 5-HT |
| AID1879778 | Drug metabolism in mouse assessed as AUC(0 to 24 hrs) for AC- 527 metabolite at 100 mg/kg by UHPLC/FT-ICR-MS analysis | 2022 | European journal of medicinal chemistry, Apr-15, Volume: 234 | Improving the treatment of Parkinson's disease: Structure-based development of novel 5-HT |
| AID1654750 | Drug level in ICR mouse brain at 10 mg/kg, iv measured after 0.5 hrs by LC-MS/MS analysis | 2020 | Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8 | Design, Synthesis, and Biological Evaluation of New Peripheral 5HT |
| AID1380714 | Antagonist activity at human 5-HT2A receptor expressed in CHO-K1 cells co-expressing Galpha16 assessed as decrease in serotonin calcium mobilization preincubated for 30 mins followed by serotonin challenge measured for 30 secs by aequorin-derived luminesc | |||
| AID1879785 | Metabolic stability in Sprague-Dawley rat liver microsomes assessed as intrinsic clearance at 100 uM preincubated for 10 mins followed by NADPH addition by LC/MS analysis | 2022 | European journal of medicinal chemistry, Apr-15, Volume: 234 | Improving the treatment of Parkinson's disease: Structure-based development of novel 5-HT |
| AID1879777 | Drug metabolism in human assessed as AUC(0 to 24 hrs) for AC- 423 metabolite at 80 mg/kg/day by UHPLC/FT-ICR-MS analysis | 2022 | European journal of medicinal chemistry, Apr-15, Volume: 234 | Improving the treatment of Parkinson's disease: Structure-based development of novel 5-HT |
| AID1654710 | Antagonist activity at 5HT2A receptor (unknown origin) expressed in HEK293 cells assessed as inhibition of serotonin hydrochloride-induced calcium flux preincubated for 1 hr followed by serotonin hydrochloride addition by calcium 6 dye based FLIPR assay | 2020 | Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8 | Design, Synthesis, and Biological Evaluation of New Peripheral 5HT |
| AID1879786 | Metabolic stability in human liver microsomes assessed as intrinsic clearance at 100 uM preincubated for 10 mins followed by NADPH addition by LC/MS analysis | 2022 | European journal of medicinal chemistry, Apr-15, Volume: 234 | Improving the treatment of Parkinson's disease: Structure-based development of novel 5-HT |
| AID1879793 | Kinetic solubility of compound | 2022 | European journal of medicinal chemistry, Apr-15, Volume: 234 | Improving the treatment of Parkinson's disease: Structure-based development of novel 5-HT |
| AID1879797 | Inhibition of CYP2C19 (unknown origin) | 2022 | European journal of medicinal chemistry, Apr-15, Volume: 234 | Improving the treatment of Parkinson's disease: Structure-based development of novel 5-HT |
| AID1879794 | Metabolic stability in dog liver microsomes assessed as compound remaining at 100 uM preincubated for 60 mins followed by NADPH addition by LC/MS analysis | 2022 | European journal of medicinal chemistry, Apr-15, Volume: 234 | Improving the treatment of Parkinson's disease: Structure-based development of novel 5-HT |
| AID1879759 | Plasma protein binding in human at 10 uM | 2022 | European journal of medicinal chemistry, Apr-15, Volume: 234 | Improving the treatment of Parkinson's disease: Structure-based development of novel 5-HT |
| AID1879816 | Drug distribution in Sprague-Dawley rat brain at 6 micromol/kg administered via gavage measured after 0.5 hr by LC-MS/MS analysis | 2022 | European journal of medicinal chemistry, Apr-15, Volume: 234 | Improving the treatment of Parkinson's disease: Structure-based development of novel 5-HT |
| AID1879767 | AUC(0 to 24 hrs) in rat at 100 mg/kg by UHPLC/FT-ICR-MS analysis | 2022 | European journal of medicinal chemistry, Apr-15, Volume: 234 | Improving the treatment of Parkinson's disease: Structure-based development of novel 5-HT |
| AID1879780 | Drug metabolism in monkey assessed as AUC(0 to 24 hrs) for AC- 527 metabolite at 100 mg/kg by UHPLC/FT-ICR-MS analysis | 2022 | European journal of medicinal chemistry, Apr-15, Volume: 234 | Improving the treatment of Parkinson's disease: Structure-based development of novel 5-HT |
| AID1879772 | Drug metabolism in monkey assessed as AUC(0 to 24 hrs) for AC-279 metabolite at 100 mg/kg by UHPLC/FT-ICR-MS analysis | 2022 | European journal of medicinal chemistry, Apr-15, Volume: 234 | Improving the treatment of Parkinson's disease: Structure-based development of novel 5-HT |
| AID1855112 | Inverse agonist activity at 5-HT2A receptor (unknown origin) | 2022 | Journal of medicinal chemistry, 08-25, Volume: 65, Issue:16 | Positron Emission Tomography (PET) Imaging Tracers for Serotonin Receptors. |
| AID1879792 | Aqueous solubility of compound at pH 7.4 | 2022 | European journal of medicinal chemistry, Apr-15, Volume: 234 | Improving the treatment of Parkinson's disease: Structure-based development of novel 5-HT |
| AID1654749 | Plasma concentration in ICR mouse at 10 mg/kg, iv measured after 0.5 hrs by LC-MS/MS analysis | 2020 | Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8 | Design, Synthesis, and Biological Evaluation of New Peripheral 5HT |
| AID1879781 | Drug metabolism in human assessed as AUC(0 to 24 hrs) for AC- 527 metabolite at 80 mg/kg/day by UHPLC/FT-ICR-MS analysis | 2022 | European journal of medicinal chemistry, Apr-15, Volume: 234 | Improving the treatment of Parkinson's disease: Structure-based development of novel 5-HT |
| AID1879757 | Antagonist activity at 5-HT2A receptor (unknown origin) expressed in CHO-K1 cells assessed as reduction in intracellular Ca2+ mobilization incubated for 15 mins by FLIPR assay | 2022 | European journal of medicinal chemistry, Apr-15, Volume: 234 | Improving the treatment of Parkinson's disease: Structure-based development of novel 5-HT |
| AID1879784 | Metabolic stability in human liver microsomes assessed as half life at 100 uM preincubated for 10 mins followed by NADPH addition by LC/MS analysis | 2022 | European journal of medicinal chemistry, Apr-15, Volume: 234 | Improving the treatment of Parkinson's disease: Structure-based development of novel 5-HT |
| AID1879769 | AUC(0 to 24 hrs) in human at 80 mg/kg/day by UHPLC/FT-ICR-MS analysis | 2022 | European journal of medicinal chemistry, Apr-15, Volume: 234 | Improving the treatment of Parkinson's disease: Structure-based development of novel 5-HT |
| AID1879761 | Metabolic stability in Sprague-Dawley rat liver microsomes assessed as compound remaining at 100 uM preincubated for 60 mins followed by NADPH addition by LC/MS analysis | 2022 | European journal of medicinal chemistry, Apr-15, Volume: 234 | Improving the treatment of Parkinson's disease: Structure-based development of novel 5-HT |
| AID1879782 | Inverse agonist activity at 5-HT2A receptor (unknown origin) expressed in mouse NIH3T3 cells using o-nitrophenyl-D-galacto pyranoside incubated for 120 hrs | 2022 | European journal of medicinal chemistry, Apr-15, Volume: 234 | Improving the treatment of Parkinson's disease: Structure-based development of novel 5-HT |
| AID1823851 | Sedative activity in ip dosed Wistar rat assessed as effect on spontaneous locomotor activity measured for 10 mins by social interaction test | |||
| AID1879796 | Inhibition of CYP2C9 (unknown origin) | 2022 | European journal of medicinal chemistry, Apr-15, Volume: 234 | Improving the treatment of Parkinson's disease: Structure-based development of novel 5-HT |
| AID1879758 | Plasma protein binding in monkey at 10 uM | 2022 | European journal of medicinal chemistry, Apr-15, Volume: 234 | Improving the treatment of Parkinson's disease: Structure-based development of novel 5-HT |
| AID1879776 | Drug metabolism in monkey assessed as AUC(0 to 24 hrs) for AC- 423 metabolite at 100 mg/kg by UHPLC/FT-ICR-MS analysis | 2022 | European journal of medicinal chemistry, Apr-15, Volume: 234 | Improving the treatment of Parkinson's disease: Structure-based development of novel 5-HT |
| AID1879820 | Antiparkinson's activity in rat assessed as reduction of DOI-induced head-twitching at 6 micromol/kg, IG measured after 1 hr | 2022 | European journal of medicinal chemistry, Apr-15, Volume: 234 | Improving the treatment of Parkinson's disease: Structure-based development of novel 5-HT |
| AID1879787 | Metabolic stability in human liver microsomes assessed as compound remaining at 100 uM preincubated for 60 mins followed by NADPH addition by LC/MS analysis | 2022 | European journal of medicinal chemistry, Apr-15, Volume: 234 | Improving the treatment of Parkinson's disease: Structure-based development of novel 5-HT |
| AID1380711 | Agonist activity at human 5-HT2A receptor expressed in CHO-K1 cells co-expressing Galpha16 assessed as increase in calcium mobilization measured for 30 secs by aequorin-derived luminescence assay relative to alpha-methylserotonin | |||
| AID1879818 | Drug distribution in Sprague-Dawley rat brain at 6 micromol/kg administered via gavage measured after 6 hrs by LC-MS/MS analysis | 2022 | European journal of medicinal chemistry, Apr-15, Volume: 234 | Improving the treatment of Parkinson's disease: Structure-based development of novel 5-HT |
| AID1879771 | Drug metabolism in rat assessed as AUC(0 to 24 hrs) for AC-279 metabolite at 100 mg/kg by UHPLC/FT-ICR-MS analysis | 2022 | European journal of medicinal chemistry, Apr-15, Volume: 234 | Improving the treatment of Parkinson's disease: Structure-based development of novel 5-HT |
| AID1879764 | Plasma protein binding in rat at 10 uM | 2022 | European journal of medicinal chemistry, Apr-15, Volume: 234 | Improving the treatment of Parkinson's disease: Structure-based development of novel 5-HT |
| AID1879765 | Inhibition of hERG potassium channel expressed in CHO cells at -80 mV holding potential by whole cell patch clamp assay | 2022 | European journal of medicinal chemistry, Apr-15, Volume: 234 | Improving the treatment of Parkinson's disease: Structure-based development of novel 5-HT |
| AID1855113 | Inverse agonist activity at 5-HT2C receptor (unknown origin) | 2022 | Journal of medicinal chemistry, 08-25, Volume: 65, Issue:16 | Positron Emission Tomography (PET) Imaging Tracers for Serotonin Receptors. |
| AID1690398 | Antagonist activity at recombinant human Ga16-coupled 5HT2A receptor expressed in CHO-K1 cells assessed as inhibition of alpha-methylserotonin-induced calcium mobilization preincubated for 15 to 30 mins followed by alpha-methylserotonin addition and measu | 2020 | European journal of medicinal chemistry, Apr-01, Volume: 191 | Multifunctional 6-fluoro-3-[3-(pyrrolidin-1-yl)propyl]-1,2-benzoxazoles targeting behavioral and psychological symptoms of dementia (BPSD). |
| AID1879770 | Drug metabolism in mouse assessed as AUC(0 to 24 hrs) for AC-279 metabolite at 100 mg/kg by UHPLC/FT-ICR-MS analysis | 2022 | European journal of medicinal chemistry, Apr-15, Volume: 234 | Improving the treatment of Parkinson's disease: Structure-based development of novel 5-HT |
| AID1879779 | Drug metabolism in rat assessed as AUC(0 to 24 hrs) for AC- 527 metabolite at 100 mg/kg by UHPLC/FT-ICR-MS analysis | 2022 | European journal of medicinal chemistry, Apr-15, Volume: 234 | Improving the treatment of Parkinson's disease: Structure-based development of novel 5-HT |
| AID1879766 | AUC(0 to 24 hrs) in mouse at 100 mg/kg by UHPLC/FT-ICR-MS analysis | 2022 | European journal of medicinal chemistry, Apr-15, Volume: 234 | Improving the treatment of Parkinson's disease: Structure-based development of novel 5-HT |
| AID1879773 | Drug metabolism in human assessed as AUC(0 to 24 hrs) for AC-279 metabolite at 80 mg/kg/day by UHPLC/FT-ICR-MS analysis | 2022 | European journal of medicinal chemistry, Apr-15, Volume: 234 | Improving the treatment of Parkinson's disease: Structure-based development of novel 5-HT |
| AID1879783 | Metabolic stability in Sprague-Dawley rat liver microsomes assessed as half life at 100 uM preincubated for 10 mins followed by NADPH addition by LC/MS analysis | 2022 | European journal of medicinal chemistry, Apr-15, Volume: 234 | Improving the treatment of Parkinson's disease: Structure-based development of novel 5-HT |
| AID1879760 | Inhibition of CYP2D6 (unknown origin) | 2022 | European journal of medicinal chemistry, Apr-15, Volume: 234 | Improving the treatment of Parkinson's disease: Structure-based development of novel 5-HT |
| AID1654709 | Antagonist activity at 5HT2A receptor (unknown origin) expressed in HEK293 cells assessed as inhibition of serotonin hydrochloride-induced calcium flux at 1 uM preincubated for 1 hr followed by serotonin hydrochloride addition by calcium 6 dye based FLIPR | 2020 | Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8 | Design, Synthesis, and Biological Evaluation of New Peripheral 5HT |
| AID1879763 | Dissociation constant, pKa of the compound | 2022 | European journal of medicinal chemistry, Apr-15, Volume: 234 | Improving the treatment of Parkinson's disease: Structure-based development of novel 5-HT |
| AID1654751 | Ratio of drug level in brain to plasma of ICR mouse at 10 mg/kg, iv measured after 0.5 hrs by LC-MS/MS analysis | 2020 | Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8 | Design, Synthesis, and Biological Evaluation of New Peripheral 5HT |
| AID1380713 | Antagonist activity at human 5-HT2A receptor expressed in CHO-K1 cells co-expressing Galpha16 assessed as decrease in serotonin-induced calcium mobilization preincubated for 30 mins followed by serotonin challenge measured for 30 secs by aequorin-derived | |||
| AID1879791 | Lipophilicity, logD of the compound at pH 7.4 | 2022 | European journal of medicinal chemistry, Apr-15, Volume: 234 | Improving the treatment of Parkinson's disease: Structure-based development of novel 5-HT |
| AID1879798 | Inhibition of CYP3A4 (unknown origin) | 2022 | European journal of medicinal chemistry, Apr-15, Volume: 234 | Improving the treatment of Parkinson's disease: Structure-based development of novel 5-HT |
| AID1879774 | Drug metabolism in mouse assessed as AUC(0 to 24 hrs) for AC- 423 metabolite at 100 mg/kg by UHPLC/FT-ICR-MS analysis | 2022 | European journal of medicinal chemistry, Apr-15, Volume: 234 | Improving the treatment of Parkinson's disease: Structure-based development of novel 5-HT |
| AID1800763 | Radioligand Binding Assay from Article 10.1124/jpet.105.097006: \\Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-10 | 2006 | The Journal of pharmacology and experimental therapeutics, May, Volume: 317, Issue:2 | Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist. |
| AID1800764 | Receptor Selection and Amplification Technology from Article 10.1124/jpet.105.097006: \\Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybuta | 2006 | The Journal of pharmacology and experimental therapeutics, May, Volume: 317, Issue:2 | Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist. |
| AID1259419 | Human 5-HT2A receptor (5-Hydroxytryptamine receptors) | 2007 | The Journal of pharmacology and experimental therapeutics, Aug, Volume: 322, Issue:2 | ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models. |
| AID1259419 | Human 5-HT2A receptor (5-Hydroxytryptamine receptors) | 2004 | The Journal of pharmacology and experimental therapeutics, Sep, Volume: 310, Issue:3 | Pharmacological characterization of AC-90179 [2-(4-methoxyphenyl)-N-(4-methyl-benzyl)-N-(1-methyl-piperidin-4-yl)-acetamide hydrochloride]: a selective serotonin 2A receptor inverse agonist. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (6.71) | 29.6817 |
| 2010's | 79 (53.02) | 24.3611 |
| 2020's | 60 (40.27) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (75.14) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 23 (14.47%) | 5.53% |
| Reviews | 38 (23.90%) | 6.00% |
| Case Studies | 5 (3.14%) | 4.05% |
| Observational | 1 (0.63%) | 0.25% |
| Other | 92 (57.86%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A 52-Week Open-label Extension Study of Pimavanserin in Adult and Elderly Subjects With Neuropsychiatric Symptoms Related to Neurodegenerative Disease [NCT03623321] | Phase 3 | 597 participants (Actual) | Interventional | 2018-07-17 | Active, not recruiting | ||
| A 52-Week Open-Label Extension Study of Pimavanserin in Children and Adolescents With Irritability Associated With Autism Spectrum Disorder (ASD) [NCT05555615] | Phase 2/Phase 3 | 228 participants (Anticipated) | Interventional | 2022-11-02 | Recruiting | ||
| A Pilot Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety and Daytime Sedation in Subjects With Parkinson's Disease With Neuropsychiatric Symptoms Treated With Pimavanserin or Low-Dose Quetiapine [NCT04164758] | Phase 2 | 11 participants (Actual) | Interventional | 2019-10-23 | Terminated(stopped due to Study enrollment impacted by COVID-19 pandemic and Sponsor terminated for business reasons) | ||
| A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder [NCT03018340] | Phase 2 | 207 participants (Actual) | Interventional | 2016-12-31 | Completed | ||
| A Double-Blind, Placebo-Controlled Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer's Disease [NCT02992132] | Phase 2 | 111 participants (Actual) | Interventional | 2016-11-30 | Terminated | ||
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia [NCT02970292] | Phase 3 | 396 participants (Actual) | Interventional | 2016-10-26 | Completed | ||
| An Open-label, 8-Week Study of Safety and Efficacy of Pimavanserin Treatment in Adults With Parkinson's Disease and Depression [NCT03482882] | Phase 2 | 47 participants (Actual) | Interventional | 2018-03-09 | Completed | ||
| A Double-blind, Placebo-controlled, Relapse Prevention Study of Pimavanserin for the Treatment of Hallucinations and Delusions Associated With Dementia-related Psychosis [NCT03325556] | Phase 3 | 392 participants (Actual) | Interventional | 2017-09-27 | Completed | ||
| A 52-Week Open-Label Extension Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease [NCT03118947] | Phase 2 | 79 participants (Actual) | Interventional | 2017-02-23 | Completed | ||
| Does Pimavanserin (Nuplazid) Improve Sleep in Patients With Parkinson Disease Psychosis? A Pilot Study [NCT05796167] | Early Phase 1 | 10 participants (Anticipated) | Interventional | 2024-01-09 | Not yet recruiting | ||
| A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia [NCT02970305] | Phase 2 | 403 participants (Actual) | Interventional | 2016-11-04 | Completed | ||
| [NCT00658567] | Phase 3 | 123 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
| Open-label Pimavanserin 34mg at Bedtime for 6 Weeks for Insomnia in Veterans With Post-traumatic Stress Disorder: Proof of Concept Study [NCT04809116] | Phase 4 | 0 participants (Actual) | Interventional | 2022-12-15 | Withdrawn(stopped due to Received alternative sources of funding.) | ||
| A 52-Week Open-Label Extension Study of Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment [NCT04000009] | Phase 3 | 235 participants (Actual) | Interventional | 2019-06-06 | Terminated(stopped due to The study was terminated for business reasons and not due to safety concerns.) | ||
| Study of Pimavanserin Efficacy for the Treatment of Impulse Control Disorders in Parkinson's Disease [NCT03947216] | Phase 2 | 130 participants (Anticipated) | Interventional | 2020-10-23 | Recruiting | ||
| Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases [NCT05357612] | Phase 4 | 75 participants (Anticipated) | Interventional | 2023-01-23 | Recruiting | ||
| A Multi-Center, Open-Label Extension Study to Examine the Safety and Tolerability of ACP-103 in the Treatment of Psychosis in Parkinson's Disease [NCT00550238] | Phase 3 | 459 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| Expanded Access Program of Pimavanserin in Patients With Parkinson's Disease Psychosis [NCT02762591] | 0 participants | Expanded Access | Approved for marketing | ||||
| Identification of a Serotonin 2A Receptor Subtype of Schizophrenia Spectrum Disorders With Pimavanserin: The Sub-Sero Proof-of-principle Study [NCT03994965] | Phase 2 | 0 participants (Actual) | Interventional | 2020-01-31 | Withdrawn(stopped due to Drug supply withdrawn) | ||
| Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment (ACP-103-054/059) [NCT03968159] | Phase 3 | 298 participants (Actual) | Interventional | 2019-04-25 | Completed | ||
| A Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of ACP-103 in the Treatment of Psychosis in Parkinson's Disease [NCT00477672] | Phase 3 | 298 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| A Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of Pimavanserin in the Treatment of Psychosis in Parkinson's Disease [NCT01174004] | Phase 3 | 199 participants (Actual) | Interventional | 2010-07-31 | Completed | ||
| Effect of Pimavanserin on Aggression and Social Cognition. [NCT05895513] | Phase 2 | 35 participants (Anticipated) | Interventional | 2024-01-31 | Not yet recruiting | ||
| A 52-Week, Open-Label, Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia [NCT03121586] | Phase 3 | 500 participants (Anticipated) | Interventional | 2017-01-31 | Recruiting | ||
| 5HT2A/C Serotonin Blockade in Parkinson's Disease [NCT00086294] | Phase 2 | 40 participants | Interventional | 2004-06-25 | Completed | ||
| [NCT00087542] | Phase 2 | 60 participants | Interventional | 2004-03-31 | Completed | ||
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia [NCT04531982] | Phase 3 | 454 participants (Actual) | Interventional | 2020-08-05 | Active, not recruiting | ||
| A Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of Pimavanserin in the Treatment of Psychosis in Parkinson's Disease [NCT06068465] | Phase 3 | 248 participants (Anticipated) | Interventional | 2023-09-27 | Recruiting | ||
| An Open-Label Safety Study of Pimavanserin in Parkinson's Disease Patients [NCT01518309] | Phase 2 | 39 participants (Actual) | Interventional | 2004-11-17 | Completed | ||
| A Single Center, Double-Blind, Placebo-Controlled Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Psychosis in Alzheimer's Disease [NCT02035553] | Phase 2 | 181 participants (Actual) | Interventional | 2013-11-30 | Completed | ||
| Pilot Feasibility Study of Pimavanserin for Insomnia in Veterans With Posttraumatic Stress Disorder [NCT04188392] | Phase 4 | 6 participants (Actual) | Interventional | 2020-01-06 | Completed | ||
| CSP #2015 - Multicenter, Randomized, Double-blind Comparator Study of Antipsychotics Pimavanserin and Quetiapine for Parkinson''s Disease Psychosis (C-SAPP) [NCT04373317] | Phase 4 | 358 participants (Anticipated) | Interventional | 2022-10-24 | Recruiting | ||
| A Randomized, Double Blind, Multi-Center Study to Assess the Antipsychotic and Motor Effects of ACP-103 When Administered in Combination With Haloperidol or Risperidone to Schizophrenic Subjects [NCT00361166] | Phase 2 | 400 participants | Interventional | 2005-08-31 | Completed | ||
| A Pragmatic Randomized Trial Comparing Antipsychotics in Lewy Body Disease [NCT05590637] | Phase 4 | 94 participants (Anticipated) | Interventional | 2022-04-22 | Recruiting | ||
| A 16-Week Open-Label Study of the Effects of Treatment With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosis [NCT04292223] | Phase 4 | 29 participants (Actual) | Interventional | 2020-02-10 | Completed | ||
| A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Pimavanserin for the Treatment of Irritability Associated With Autism Spectrum Disorder [NCT05523895] | Phase 2/Phase 3 | 228 participants (Anticipated) | Interventional | 2022-08-09 | Recruiting | ||
| Pimavanserin for Insomnia in Veterans With Post-traumatic Stress Disorder [NCT05441280] | Phase 2 | 60 participants (Anticipated) | Interventional | 2023-06-26 | Recruiting | ||
| A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled, Safety Study of Pimavanserin Therapy in Adult and Elderly Subjects Experiencing Neuropsychiatric Symptoms Related to Neurodegenerative Disease [NCT03575052] | Phase 3 | 784 participants (Actual) | Interventional | 2018-05-21 | Completed | ||
| An Open Label, Proof-of-Principle, Pilot Study to Evaluate Pimavanserin for the Treatment of Motor and Behavioral Symptoms of Tourette Syndrome [NCT04794413] | Early Phase 1 | 10 participants (Actual) | Interventional | 2018-11-12 | Completed | ||
| A Target Engagement Study of Pimavanserin for Behavioral Inflexibility With Open Label Trial for Rigid Rigid-compulsive Behavior in Adolescents and Adults With Autism [NCT05999240] | Phase 2 | 30 participants (Anticipated) | Interventional | 2023-12-01 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||